Skip to content

Our Pipeline

Bluejay is passionate about shifting the treatment paradigms for patients with difficult viral and liver diseases.

We’re starting by making a functional cure for CHB a reality and developing a life-changing treatment for CHD – both have been in the shadow of other infectious diseases for too long.

Bluejay Therapeutics' pipeline of viral disease programs and liver disease programs

Viral Disease Programs

Our lead program, BJT-778, is a best-in-class monoclonal antibody against hepatitis B surface antigen (anti-HBsAg mAb). BJT-778 is designed to treat CHB and CHD by significantly reducing serum HBsAg, thereby alleviating immune cell exhaustion and allowing the immune system to control the infection.

Cavrotolimod is a proprietary spherical toll-like receptor 9 (TLR9) agonist designed to trigger innate and adaptive immune responses.

BJT-628 is an orally bioavailable, liver-targeted HBV transcript inhibitor. This small molecule is designed to effectively reduce hepatitis B surface antigen (HBsAg) production from HBV-infected cells, and is expected to be an effective combination partner for BJT-778.

Liver-Targeting Advanced Platform

Bluejay L-TAP

Bluejay is advancing its proprietary Liver-Targeting Platform, known as L-TAP. This platform enables the precise delivery of oral small molecules to the liver, resulting in enhanced efficacy while improving safety by minimizing exposure to sensitive tissues.

Bluejay boasts a wealth of expertise in L-TAP, which has already been instrumental in the development of innovative programs, including the liver-targeted HBV transcript inhibitor, BJT-628, and early-stage NASH initiatives.

Clinical Trials

Now Enrolling

A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection

Learn more

Keting Chu

Founder, Chief Executive Officer and Chairman of the Board

Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close $550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was previously a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for $1.5B, Kite by Gilead for $12B and Stemline by Menarini for $677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that keting led the team from discovery to phase I clinical trials are in phase II and III testing now.

Keting received her MD in Sun Yat-Sen Medical University where she specialized in infectious diseases in China, and Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.